Glance Editorial Team

 of published studies dealing with mask-associated dry eye (MADE) found evidence that face mask usage causes an increase in symptoms of dry eye disease (DED). Since mask usage continues to be the norm in multiple settings, the authors call for continued research into the effects on the ocular surface.

The paper reviewed a total of 67 articles on 

 that consisted of “studies regarding the use of face masks and outcome measures pertaining to the ocular surface.” Articles were narrowed down by identifying those containing a combination of two keyword groups: “dry eye,” “ocular,” “cornea” or “tear” and “mask.”

Ocular Surface Disease Index (OSDI) and Standard Patient Evaluation of Eye Dryeness (SPEED) scores worsened with the extended use of face masks across multiple studies of healthy patients, while many studies found that tear break-up time (TBUT) and Schirmer 1 worsened after extended usage, while others had more contradictory results.

In the few studies of mask usage by patients with DED, they were more likely to report a worsening of their symptoms after prolonged mask usage.

Most studies investigating MADE used a healthy patient population rather than a population of patients already diagnosed with DED.

Face mask usage isn’t going away, the authors noted, and so continued research on the impact of face masks on the ocular surface is necessary. They wrote: “Studies should be controlled for [quarantine-related stress, depression and anxiety] in order to truly evaluate the prevalence and characteristics of MADE.”

In addition, the authors urged the eyecare community to come to a consensus on a set diagnostic criteria for MADE.

They concluded: “Despite common MADE symptoms in many patients, frequent wearing of face masks should not be dissuaded, as it is a crucial protective factor against COVID-19 and other respiratory viruses’ transmission. Instead, awareness among ophthalmologists of this condition and possible measures should be increased.”

Review of 67 studies finds a correlation between mask usage and worsening dry eye in healthy and DED patients.

Extended mask wear linked with worsening dry eye

Nidek Co., Ltd., and optical technology company Hoya Vision Care have 

nto a global alliance to jointly give eye care professionals (ECPs) a complete portfolio of optical instruments and products as a full-service provider for patient care.

Nidek specializes in designing, manufacturing, and distributing ophthalmic and optical lens-edging equipment. Hoya Vision’s focus ranges from offering ECPs high-quality lenses, integrated systems, training, and other industry services.

Has Nidek made any products I’ve heard of?

Probably—look no further than the exam lane at your slit lamp microscope or the OPD-Scan III for entrance testing. The company’s portfolio includes ophthalmic diagnostic equipment, customized refractive surgery tools, and ophthalmic lasers for an array of conditions within the cataract, cornea, glaucoma, and retina spaces.

According to both companies, the partnership is 

, which grants them access to a wide range of products (now including Nidek’s), technology, and business services to use to their practices’ advantage.

The partnership has the potential for ECPs to gain access to leverage a broader range of more personalized ophthalmic products, including high-performing lenses to further enhance patient care.

New agreement focuses on offering patients a wider array of ophthalmic services.

Nidek

Hoya Vision Care

Nidek and Hoya Vision Care launch global partnership 

Researchers from Trinity College in Dublin have 

 that optimizing NDI1 (ophNdi1), a new potential gene therapy, could be beneficial for multiple eye diseases with mitochondrial deficiencies, including age-related macular degeneration (AMD), glaucoma, and Leber hereditary optic neuropathy (LHON).

A previous study conducted by the same group showed the benefit of adeno-associated virus (AAV)-delivered NDI1 by intravitreal injection to protect retinal ganglion cells in a rotenone-induced mouse model of optic neuropathy.

What role does mitochondria play into this?

Mitochondria are membrane-bound organelles known to manage energy production in cells and contain their own DNA (inherited from only the mother). In this study, investigators found that their performance was dampened in patients diagnosed with neurodegenerative disorders inclusive of the retina and optic nerve-related diseases.

The research team used silico analyses to modify a total of 329 codons of the yeast-derived NDI1 gene to 

 in mammalian cells and codon substitutions to prevent potential immunogenicity, which, as a result, create ophNdi1.

The gene therapy accesses cells where mitochondria failed to deliver a code that revitalized the mitochondria, enhancing energy output and the ability to support visual functions.

Researchers looked at the effect of AAV-ophNdi1 on patient-derived fibroblasts taken from the  biopsies of three male LHON patients. These were compared to sex- and age-matched control fibroblast cell lines of individuals with no history of mitochondrial or visual dysfunction.

When compared to NDI1, ophNdi1 more efficiently decreased reactive oxygen species (ROS) and increased cellular bioenergetics in vitro—counteracting two key causes behind mitochondrial dysfunction.

Evaluation in a mouse model found that intravitreal injection of AAV-ophNdi1 substantially reduced retinal ganglion cell death and, as a result, led to a significant preservation of retinal function.

AAV-ophNdi1 also rescued and reduced adenosine triphosphate (ATP) and oxygen consumption rates observed in LHON patient-derived fibroblasts, showcasing the potential of ophNdi1 as a candidate genetic therapy for ocular diseases associated with mitochondrial deficiencies.

Study authors stated their findings support the use of ophNdi1 as a novel gene therapeutic approach for treating multiple eye diseases, as well as suggest that ophNdi1’s therapeutic platform could be a target treatment for other eye diseases plagued by mitochondrial dysfunction.

Further, this could be the next of many logical steps towards the potential development of personalized genetic therapies.

Gene therapy study on retinal and optic nerve-related mitochondrial dysfunction shows promise.

Gene therapeutic approach has potential to treat various eye diseases

Clearside Biomedical, Inc announced the release of positive 6-month data from its extension study of the 

 via Clearside’s proprietary SCS Microinjector, for the treatment of patients diagnosed with neovascular age-related macular degeneration (wet AMD).

The data includes both the 3-month dose-escalation period and 3-month extension study.

CLS-AX (axitinib injectable suspension) is a tyrosine kinase inhibitor (TKI) currently approved to treat renal cell cancer. It achieves pan-VEGF blockade by directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. With suprachoroidal administration of axitinib, there is the potential to achieve prolonged duration and targeted delivery to affected tissue layers.

Watch the video below for a demonstration. 

Back to the Extension Study … talk about the results.

Among the 12 participants in cohorts 3 and 4, there was a 

 in treatment burden compared to the average number of monthly injections in the 6 months prior to receiving CLS-AX administration. Further, the number of patients not requiring additional therapy dropped from 92% at ≥ 3 months to 50% at > 6 months.

No serious adverse events (AEs) or treatment emergent adverse events were reported (n=14) in all cohorts.

Nope! CLS-AX also showed a stable mean best-corrected visual acuity (BCVA) and stable mean central subfield thickness (CST) at the 6-month mark.

 on launching the ODYSSEY phase 2 clinical trial, which will be a multicenter, randomized, double-masked phase 2b trial assessing an estimated 110 treatment-naïve patients with wet AMD.

Latest data finds a 77% to 85% reduction in treatment burden over time period.

Clearside Biomedical

Positive 6-month results reported in OASIS extension trial for CLS-AX

 from Johns Hopkins Medicine has linked low blood sugar levels to a worsening of diabetic retinopathy (DR) in retinal cells cultured in low glucose.

Tight glycemic control (TGC) controls the blood glucose level to within the 4.4–6.1 mmol/L range in order to avoid hyperglycemic episodes. It is usually used with the intention of preventing or delaying diabetic microvascular disease, but has also been associated with worsening DR, as have transient episodes of high and low glucose concentration.

TGC is a common strategy for diabetic management to reduce the progression of diabetic microvascular disease. However, it may also induce hypoglycemic episodes, which can paradoxically increase DR progression.

The study explored the effects of acute episodes of hypoglycemia on the retina and the subsequent effects on the development and progression of diabetic eye disease (DED).

Researchers analyzed the protein levels in intact retinas and retinal cells from mice and humans in low glucose.

First, that the glucose transporter GLUT1 is a key player in metabolic regulation of Müller cells in the retina; and second, that HIF1α accumulates during hypoglycemic episodes—increasing the chance for development of DR .

As a study performed on cultured cells, the authors noted the lack of patient data as a major limitation. They were also “unable to identify the signaling pathway(s) connecting cellular detection of low glucose with the increase in nuclear accumulation of HIF-1α that remains.”

These findings have implications for future research into methods for controlling or preventing the progression of DR.

As the authors noted: “While TGC remains essential for preventing microvascular injury in patients with diabetes, these findings suggest that this should not be achieved at the expense of glycemic stability.”

New study finds ties between tight glycemic control and worsening of diabetic retinopathy.

Why low blood sugar worsens diabetic eye disease

Visionary Optics announced the launch of Europa Tangent, its latest scleral lens featuring a customizable design, three-zone step system, and a streamlined fitting process.

 includes a single-curve scleral landing zone curve crafted to mimic the natural slope of the scleral surface, which allows for a smoother, softer transition to the landing zone. Driven by profilometry data and Visionary Optics’ scleral shape classification expertise, the lens is patterned after their proprietary free-form lens design.

Indeed. Visionary Optics already launched its 

 lens that also features customization with toric haptics, a spherical lens design, a presbyopia option, astigmatic correction (front to back toric integration), and the company’s Precision Lift technology that allows for elevation into the mid-peripheral zone of the lens.

The three-zone step system creates a more simplified process by allowing for independent adjustments to be made in the central, limbal, and landing zone in 50μ increments—without any effects on other lens parameters (up to +300μ).

What if I’m new to scleral lens fitting?

The lens was designed with new and season fitters in mind.  With a simplified design, it offers streamlined fitting and the added benefit of advanced customization retained from the established family of Visionary Optics scleral lenses.

New lens features a customizable design, three-zone step system, and a streamlined fitting process.

Visionary Optics

Visionary Optics launches Europa Tangent scleral lens 

Bausch + Lomb Corporation and biomedical laser company Modulight Corporation have received FDA approval for the equivalent use of Modulight’s ML6710i photodynamic laser with Bausch + Lomb’s Visudyne (verteporfin for injection) photodynamic therapy (PDT) to treat patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).

Modulight’s photodynamic laser is a transportable ophthalmic laser that includes a beam-shaping unit capable of fitting into standard slit lamps. The laser light is formed into a uniform circular spot to deliver treatment of Visudyne efficiently. It is operable via an iPad mobile application. (

Visudyne is an injectable photosensitizer drug indicated for patients with—aside from subfoveal CNV due AMD—pathologic myopia or presumed ocular histoplasmosis. When used with the ML6710i, the recommended light dose is 50 J/cm2  of neovascular lesion administered at an intensity of 600 mW/cm2, with the laser light wavelength at 689±3 nm.

Beginning at 15 seconds after the start of Visudyne infusion, the light dose should be administered over the course of 83 seconds. (

Bausch + Lomb reported approximately 10% to 30% of patients reported adverse events (AEs) surrounding the injection site (pain, edema, inflammation, rashes) and visual disturbances (blurred vision, light flashes, decreased visual acuity and visual field defects). (

What’s the significance of this approval?

The combined delivery of ML6710i with Visudyne addresses an unmet need for patients with wet AMD with persistent fluid. Further, this modernized photodynamic laser with PDT could be an alternative or complementary therapy to existing antiangiogenic medications in the CNV treatment armamentarium.

Bausch + Lomb expects it to be available in the first half of 2023.

Photodynamic laser and therapy target treating patients with predominantly classic subfoveal choroidal neovascularization due to AMD.

Bausch + Lomb

Modulight Corporation

FDA approves ML6710i photodynamic laser for use with Bausch + Lomb’s PDT 

A joint Brazilian study evaluated thalamocortical connections that cause the cross-modal plasticity found in congenitally blind (CB) individuals.(

Analyzing the brains of people with congenital blindness allowed investigators to understand how the brain built and maintained its structural organization and hierarchy of processing without one of the major sensory input sources.

Many brain alterations can occur in response to a lack of visual input. Those with CB often experience atrophy of the optic chiasm and reduced microstructural integrity of optic radiations and the geniculocalcarine tract.

Researchers looked to investigate the potential for alternative neural connections by using magnetic resonance imaging (MRIs) to analyze the thalamic remapping of cortical connections in people with congenital blindness.

To organize the data, six cortical masks—prefrontal, precentral, postcentral, posterior parietal, occipital, and temporal areas—were predefined using the Harvard-Oxford Atlas. Probabilistic tracking was conducted with a PROBTRACKX tool.

Researchers calculated the number of samples reaching each target mask as a proportion of the total number of samples reaching any target mask. They then performed hard segmentation of each thalamus based on its connectivity to each of the six ipsilateral cortical areas, and then a voxel-wise analysis of the thalamocortical connectivity to compare the results between the two groups. (

A total of 20 participants were split into two groups: CB group included six males and four females (all who could read Braille) with a mean age of 31.8 ; the control group had a mean age of 32.2 and the same ratio of males and females.

All participants were right-handed, had no history of neurologic or psychiatric diseases, and were not taking brain-active medication.

Researchers noted structural connectivity changes in the thalamus. Further, the thalamus area that connects with vision was found to be weaker/smaller in CB participants, giving space to connections with hearing (which were strengthened in comparison to the non-visually impaired participants.

Increased thalamo-temporal connectivity was observed, specifically in the medial geniculate nucleus (MGN), lateral geniculate nucleus (LGN), and the pulvinar bilaterally. Additionally, decreased thalamo-occipital connectivity was noted, particularly in the left pulvinar and lateral posterior nucleus.


Differences in white matter microstructure were recorded between the control and CB groups. A whole-brain analysis showed decreased fractional anisotropy (FA) in the major white matter structures connecting the occipital cortex in the CB group. Further analysis restricted to the whole thalamus also revealed a diffuse decrease in FA in the CB group.

This is the first time a study noted an alternative mapping in connectivity of the thalamus with the occipital and temporal cortices in humans. This plastic reorganization may be a mechanism that explains how nonvisual stimuli reach and activate the visual cortex in congenitally blind people.

The study authors noted that neuroimaging studies such as this allow researchers to navigate the brain's structure and better understand the diversity of brain plasticity, which can also pave the way for new visual rehabilitation initiatives. (

Researchers evaluated thalamocortical connections that cause cross-modal plasticity in this patient population.

Why do patients with congenital blindness show visual processing activity in the brain?

The FDA has granted Huida Gene Therapeutics clearance for its investigational new drug (IND) application in support of launching a multi-national trial assessing HG004 as treatment for patients with inherited retinal dystrophies (IRD) linked to RPE65 mutations.

The global, clinical-stage biotechnology company is based in Shanghai and New Jersey, and is focused on the development of clustered regularly interspaced short palindromic repeats (CRISPR)-based genetic medicine

HG004 is a novel ophthalmic injection designed to treat 

A head-to-head, preclinical study compared equal dosages of HG004 and adeno-associated virus serotype 2 (AAV2). Retinal function recovery was found to increase by 67.6% for HG004 and 35.8% for AAV2 products when assessed using an RPE65 gene knockout murine disease model. 

Essentially, yes. HG004 performed better with transduction efficiency and substantial vision loss restoration at the level of the retinal pigment epithelium (RPE) comparatively to AAV2. HuidaGene stated that it shows the potential for lowering the total number of vector doses, leading to a reduced risk for ocular adverse events (AEs) in humans. (

According to HuidaGene, the HG004 program is looking to create a one-time, non-AAV2 gene replacement to restore, treat, and prevent pediatric/adult blindness in patients already experiencing severe visual impairment/blindness due to 

The multi-national, multi-center, multiple-cohort, dose-finding study will evaluate adult and pediatric patients with 

 retinopathies using one master protocol. The safety, tolerability, efficacy, and long-term clinical durability of one HG004 injection is being assessed for up to 52 weeks.

Primary endpoints include adverse events, ophthalmic examinations, and certain laboratory measures.

Patients’ visual function will be observed through a multiluminance mobility test (MLMT) that will require them to maneuver a mobility course via various light levels. The company plans on launching the trial within the first half of 2023.

Following completion of the primary multinational study, participants will continue to receive evaluation through a long-term follow-up study on HG004.

Company plans to analyze HG004 as treatment for patients with inherited retinal dystrophies linked to the RPE65 mutations.

FDA clears HuidaGene for IND, multi-national IRD trial

suggests that taking longer breaks or with different frequencies may be the answer to minimizing digital eye strain —a major contrast to the long-held 20-20-20 rule.

The practice recommends for a person working on any digital device to stare at an object at least 20 feet away for at least 20 seconds, every 20 minutes. The thought is that, by taking frequent breaks, it could reduce digital eye strain symptoms. (

Investigators enrolled 30 participants (25 female; mean age of 24.1) who attended four sessions that were each separated by a 24-hour period, within a 4-week time period. Sessions included a 40-minute reading task that participants completed using an iPad tablet computer; each task consisted of reading out loud and identifying words beginning with specific letters.

Participants were permitted to take breaks during each session by looking out the window at a distant target for 20 seconds. Breaks could be taken every 5, 10, and 10 minutes, respectively, for the first three sessions. No breaks were allowed during the last 40-minute session. (

Participants completed a questionnaire about their ocular and visual symptoms both before and after each session. Ratings were based on a scale of 0 (none) to 10 (very severe).

Investigators found that interval variation between breaks did not result in a significant change in reading speed (P = .93), reading accuracy (P = .55) and reported symptoms (P = .70). However, they did observe a significant increase in post-task symptoms (eye strain and blurred vision) for all four trials (P <.001).

The authors concluded that the findings provide no support for the 20-20-20 rule as an effective therapeutic prevention for digital eye strain. Further, they expressed no surprise, since there appears to be little or no existing evidence to support the use of the 20-20-20 rule to minimize symptoms.

They cautioned that these findings should not be interpreted as evidence that taking breaks can not be helpful in reducing digital eye strain.

The authors recommended additional research be conducted for assessing the effects of longer breaks.

New research finds that longer breaks could be the answer to minimizing effects.

20-20-20 rule may not actually help digital eye strain

A new microfluidic contact lens prototype developed by researchers from the UCLA Terasaki Institute for Biomedical Innovation (TIBI) is targeting the prevention of contact lens-induced dry eye (CLIDE).

CLIDE arises from an insufficient flow of tears from the outer surface of a contact lens to the surface located behind the lens, inducing signs and symptoms of ocular surface dryness. This can cause tear volume reduction, tear film instability, an increase in tear osmolarity, ocular discomfort, and visual disturbances.

They sought to develop a contact lens using microchannels that could transport the tear flow of the pre-lens tear film (PrLTF) to the post-lens ocular surface by using normal eye blinking in order to prevent eye dryness. (

The lens mold was created from a silicone polymer mixture, which made for an easy removal of the lens cast from it via gently bending the mold, and required a 12-hour, hot water soak in order to remove the lens.

The prototype featured high-quality, smooth microchannels, a thinner lens, and reservoirs (created using a custom device) at the ends of each microchannel for liquid flow. A capping lens layer was added using water-soluble glue. (

The prototype lenses underwent several in vitro experiments using a device that mimicked a human eye blink. The device was embedded within the lens to generate tear flow (via artificial eyelid pressure).

The scientists found that microchannels with square cross-sections arranged on the lens surface in a circular pattern allowed for the ideal tear flow.

 achieved a proof-of-concept validation for the prototype lens in leading tear flow from the lens surface to the underside and, as a result, preventing dry eye. 

However, they recommended further experimentation to test the microfluidic prototype lenses in patients and in animal models.

New contact lens prototype targets ocular dryness via tear flow.

Prototype designed to prevent contact lens-induced dry eye 

 announcement, Harrow has officially acquired the exclusive U.S. rights to five FDA-approved branded ophthalmic products from Novartis. This marks the 

 between the two companies in less than a year.

The transaction includes: Ilvero (nepafenac ophthalmic suspension) 0.3%; Nevanec (nepafenac ophthalmic suspension) 0.1%; Vigamox (moxifloxacin hydrochloride ophthalmic suspension) 0.5%; Maxidex (dexamethasone ophthalmic suspension) 0.1%; and Triesence (triamcinolone acetonide injectable suspension) 40 mg/ml. (

Harrow paid a total of $130 million at closing. An additional $45 million payment will be due once Triesence is commercially available, likely in the second half of 2023.

Novartis will continue to sell the five products in the U.S. market during a 6-month non-disclosure agreement (NDA) transfer period, during which it will transfer all net profits to Harrow.

After the period, Harrow will take control of U.S. market dealings and begin the process of having third-party manufacturers for the products.

This acquisition just gave Harrow a major stake in the U.S. ophthalmic pharmaceutical market.

Deal is worth up to $175 million; includes an additional payout upon the commercial availability of Triesence later this year.

Harrow

Novartis

Harrow completes acquisition of exclusive US rights for 5 ophthalmic products

The Centers for Disease Control and Prevention (CDC) has issued a statement calling for the immediate discontinuation of the use of EzriCare Artificial Tears for dry eye treatment following reported infections across the country.

The CDC stated that it is currently investigating a cluster in multiple states of Verona Integron‐mediated Metallo‐β‐lactamase (VIM)‐ and Guiana‐Extended Spectrum‐β‐Lactamase (GES)‐ producing carbapenem‐resistant Pseudomonas aeruginosa (VIM‐GES‐CRPA) that are linked to various infection sites (inclusive of ocular tissues). (

When, where, and how were they identified?

VIM‐GES‐CRPA was reported in 50 patient cases (with 56 isolates), identified from May 17, 2022 to January 19, 2023, in 11 states: California, Colorado, Connecticut, Florida, New Jersey, New York, New Mexico, Nevada, Texas, Utah, and Washington. Of the 50 cases, 38 were part of four facility clusters. 

Isolates were identified from clinical cultures of several specimens collected, including of the cornea, urine, blood, and rectal swabs.

The company’s artificial tears (carboxymethylcellulose sodium 10 mg) are preservative-free, over-the-counter (OTC), and dispensed in multi-dose bottles.

According to the CDC, review of common exposures among patients determined that the majority of patients had used artificial tears prior to infection, with EzriCare Artificial Tears being the most common brand reported.  

Laboratory testing found an initial presence of VIM-CRPA in opened bottles of the tears; further analysis is being done to identify a potential match to the outbreak strain. (

The CDC reported permanent vision loss as a result of ocular infection, hospitalization, as well as the death of one patient (from a bloodborne infection).

Any clinicians and patients should stop use of the EzriCare Artificial Tears until laboratory analyses and epidemiological studies are completed,

For any laboratories that identify VIM-CRPA or carbapenem‐resistant

 from an ocular specimen, they should send the isolate to the Antimicrobial Resistance Laboratory Network for further characterization.

ECPs are recommended to stop use of EzriCare Artificial Tears following reports of permanent vision loss in patient cases across the country.

CDC advises immediate discontinuation of EzriCare Artificial Tears

it is launching Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05%., a therapeutic generic equivalent to Durezol (difluprednate ophthalmic emulsion 0.05%), to the US market.

The multinational pharmaceutical company is based in Hyderabad, India, with a portfolio including generics, branded generics, biosimilars, and over-the-counter products. They largely focus on therapeutic areas such as gastrointestinal, diabetology, cardiovascular, oncology, pain management, and dermatology, with a presence in the US market as well as in India, China, Brazil, and Europe.

A registered trademark of Novartis, Durezol is a topical corticosteroid indicated for treating inflammation and pain associated with ocular surgery and endogenous anterior uveitis.

For ocular surgery, one drop is instilled into the conjunctival sac of the affected eye, QID, starting 24 hours after surgery and continuing postoperatively for two weeks, then for twice a day for a week followed by a taper down schedule based on response. For uveitis, one drop is instilled into the affected eye’s conjunctival sac, QID, for 14 days, then followed by a taper-down regimen dependent on case presentation.


Recently approved by the FDA, the formulation is also indicated for treating inflammation and pain associated with ocular surgery as well as endogenous anterior uveitis. Similar to Durezol, the product is available in 5 ml bottles in case packs of 24.

According to the IQVIA, Durezol and the generic accumulated an estimated $40 million MAT (moving annual total) in U.S. sales for the 12-month period ending in November 2022.

With a similar formulation and indication comparative to the branded version, it will likely be less expensive, which might minimize certain barriers such as insurance prior authorization requests— leading to potential improvements in insurance coverage and overall patient access.

Dr. Reddy’s Laboratories formulation is now another competitive option for treating postoperative inflammation and pain associated with ocular surgery and endogenous anterior uveitis.

HEADLINES

Nidek and Hoya Vision Care launch global partnership

Gene therapeutic approach has potential to treat various eye diseases

Positive 6-month results reported in OASIS extension trial for CLS-AX

FEATURED

Extended mask wear linked with worsening dry eye

TRENDING

20-20-20 rule may not actually help digital eye strain

Prototype designed to prevent contact lens-induced dry eye

Harrow completes acquisition of exclusive US rights for 5 ophthalmic products

CDC advises immediate discontinuation of EzriCare Artificial Tears

Business

Nidek and Hoya Vision Care launch global partnership

Amazon launches online subscription service for generic drugs

Are glaucoma and obstructive sleep apnea connected?

Viatris officially acquires Oyster Point Pharma, Famy Life Sciences

Research

Extended mask wear linked with worsening dry eye

Gene therapeutic approach has potential to treat various eye diseases

Why low blood sugar worsens diabetic eye disease

Why do patients with congenital blindness show visual processing activity in the brain?

Pipeline

Positive 6-month results reported in OASIS extension trial for CLS-AX

FDA clears HuidaGene for IND, multi-national IRD trial

Prototype designed to prevent contact lens-induced dry eye

FDA accepts Oxular’s IND for DME treatment

Products

Visionary Optics launches Europa Tangent scleral lens

FDA approves ML6710i photodynamic laser for use with Bausch + Lomb’s PDT

Generic version of Durezol launches in US

CDC advises immediate discontinuation of EzriCare Artificial Tears

Legal

Court sides with Regeneron in Eylea patent case against Novartis

Bausch + Lomb to purchase AcuFocus

Archives

Hello 2023 — Weekly Glance

Can we treat uveitis without steroids? — Weekly Glance

Can I have one dilation drop instead of two? — Weekly Glance

Are those dilation reversal drops available yet? — Weekly Glance